LYN mutation
|
NSCLC
|
LYN mutation
|
NSCLC
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
|
LYN mutation
|
Melanoma
|
LYN mutation
|
Melanoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|